Table 5.
Authors | Year | ADAMTS | PrCa Platform | Role |
---|---|---|---|---|
Binder et al. [221] | 2020 | ADAMTS-15 | Yes—Prostate samples, prostate cell lines and mice | ADAMTS-15 expressed and active in PrCa samples. Enforced ADAMTS-15 expression decreased migration and proliferation but increased survival in vitro and suppressed tumor growth in mice. |
Cross et al. [222] | 2005 | ADAMTS-1, 4, 5, 9 and 15 | Yes—Prostate cell lines | ADAMTS-1, ADAMTS-4, ADAMTS-5, ADAMTS-9 and ADAMTS-15 expressed in PrCa. |
Gustavsson et al. [185] | 2008 | ADAMTS-1 * | Yes—Prostate cell lines and mice | ADAMTS-1 expression decreased in PrCa cell line with enhanced angiogenic and tumorigenic properties, compared to parent. |
Gustavsson et al. [220] | 2009 | ADAMTS-1 | Yes—Prostate samples | ADAMTS-1 expression decreased in prostate cancer cells compared to benign prostate glands. No correlation with Gleason score, but expression lower in patients with metastatic disease. |
Gustavsson et al. [219] | 2010 | ADAMTS-1 | Yes—Prostate cell lines and mice | ADAMTS-1 ablation decreased tumor growth, but in other PrCa cells enforced expression inhibited tumor growth. |
Jennbacken et al. [65] | 2009 | ADAMTS-1 | Yes—Prostate cell lines and mice | ADAMTS-1 expression increased in slow growing tumors in mice. |
Kim et al. [179] | 2012 | ADAMTS-1 * | Yes—Prostate samples | ADAMTS-1 mRNA overexpressed in PrCa samples. |
Molokwu et al. [223] | 2010 | ADAMTS-1 and 15 | Yes—Prostate cell lines | ADAMTS-15 (but not ADAMTS-1) expressed in PrCa. |
* Included in at least one other table.